| Nia Health–Adesso: investment, 202305 seed financing round totalling €3.5m incl co-investor Adesso Ventures |
2023-05-15 |
| Nia Health–High-Tech Gründerfonds: investment, 202305 seed financing round totalling €3.5m incl lead investor HTGF |
2023-05-15 |
| Nia Health–PERSON: investment, 202305 seed financing round totalling €3.5m incl co-investor fund of Kurt Schwarz |
2023-05-15 |
| Nia Health–Piabo PR: public relations, 202305 service existent by Piabo PR |
2023-05-15 |
| Nia Health–SEVERAL: investment, 202305 seed financing round €3.5m led by HTGF |
2023-05-15 |
| Nia Health–Ventura BioMed Investors: investment, 202305 seed financing round totalling €3.5m incl co-investor Venture BioMed Investors |
2023-05-15 |
| Repare Therapeutics–Vivlion: gene editing, 202305– supply of PRICSR CRISPR gRNA libraries for synthetic lethal screening by Vivlion |
2023-05-11 |
| UCB–Ariceum Therapeutics: targeted radiopharmaceuticals, 202305– collab strategic r+d for TRTs for solid tumours + immune-related diseasees |
2023-05-11 |
| Bayer–Bicycle Therapeutics: Bicycle technology, 202305– strategic collab $45m upfront + $1.7b milestones for targeted radiopharmaceuticals |
2023-05-10 |
| DiogenX–AdBio Partners: investment, 202305 financing round Series A totalling €27.5m incl existing + co-investor AdBio Partners |
2023-05-10 |
| DiogenX–Boehringer: investment, 202305 financing round Series A totalling €27.5m incl existing + co-lead investor Boehringer Ingelheim Venture Fund |
2023-05-10 |
| DiogenX–Juvenile Diabetes Research Foundation: investment, 202305 financing round Series A totalling €27.5m incl existing + co-investor JDRF T1D Fund |
2023-05-10 |
| DiogenX–Lilly: investment, 202305 financing round Series A totalling €27.5m incl new + co-investor Eli Lilly |
2023-05-10 |
| DiogenX–Omnes Capital: investment, 202305 financing round Series A totalling €27.5m incl new + co-investor Omnes |
2023-05-10 |
| DiogenX–Roche: investment, 202305 financing round Series A totalling €27.5m incl new + co-lead investor Roche Venture Fund |
2023-05-10 |
| DiogenX–SEVERAL: investment, 202305 financing round Series A €27.5m led by BIVF + Roche Venture Fund |
2023-05-10 |
| Ascend GCTx–4BIO Ventures: investment, 202305c financing round Series A incl co-investor 4BIO Capital |
2023-05-09 |
| Ascend GCTx–Ajinomoto: investment, 202305c financing round Series A incl co-investor Ajinomoto Co Inc |
2023-05-09 |
| Ascend GCTx–Carlyle: investment, 202305c financing round Series A incl co-lead investor Abingworth |
2023-05-09 |
| Ascend GCTx–Cathay Capital: investment, 202305c financing round Series A incl co-investor Cathay Health |
2023-05-09 |
| Ascend GCTx–DCVC: investment, 202305c financing round Series A incl co-investor DCVC Bio |
2023-05-09 |
| Ascend GCTx–Deerfield: investment, 202305c financing round Series A incl co-investor Deerfield Management |
2023-05-09 |
| Ascend GCTx–Digitalis Ventures: investment, 202305c financing round Series A incl co-investor Digitalis Ventures |
2023-05-09 |
| Ascend GCTx–Petrichor Healthcare: investment, 202305c financing round Series A incl co-lead investor Petrichor |
2023-05-09 |
| Ascend GCTx–Ramarketing: public relations, 202305 service existent Ramarketing is media contact |
2023-05-09 |
| Ascend GCTx–SEVERAL: investment, 202305c financing round Series A bringing total raised to $132.5m led by Abingworth + Petrichor |
2023-05-09 |
| Cambridge Research Biochemicals–Biosynth: investment, 202305 acquisition of CRB by Biosynth |
2023-05-09 |
| PolyPeptide–Numaferm: peptide synthesis, 202305– collab €na Preferred Partner Collaboration Agreement for peptide development + production |
2023-05-09 |
| Roche–Zion Pharma: tyrosine kinase inhibitor, 202305– acqisition ww rights $70m ufpront + near-term MS + $610m milestones + royalties to ZN-A-1041 |
2023-05-09 |
| Midwest Biosolutions–Bionter: analytical instruments, 202305– collab Midwest Bio to promote + sell Bionter products + services in the US |
2023-05-08 |
| Zontal–Bruker: investment, 202305 acquisition €na of Zontal by Bruker |
2023-05-08 |
| Bicycle Therapeutics–Helmholtz: Bicycle radio conjugates, 202305– collab to discovery + develop BRCs for a range of oncology targets with DKFZ |
2023-05-04 |
| Medigene–MC Services: public relations, 202305 service existent by MC Services |
2023-05-03 |
| Anavo Therapeutics–ABP (NL): investment, 202305 seed financing round extenstion totalling €8.5m incl existing investor Inkef Capital |
2023-05-02 |
| Anavo Therapeutics–Bioqube Ventures: investment, 202305 seed financing round extenstion totalling €8.5m incl existing investor Bioqube Ventures |
2023-05-02 |
| Anavo Therapeutics–Merck (DE): investment, 202305 seed financing round extenstion totalling €8.5m incl existing investor M Ventures |
2023-05-02 |
| Anavo Therapeutics–Merck (US): investment, 202305 seed financing round extenstion totalling €8.5m incl new investor MRL Ventures Fund |
2023-05-02 |
| Anavo Therapeutics–Otsuka: investment, 202305 seed financing round extenstion totalling €8.5m incl existing investor Taiho Ventures |
2023-05-02 |
| Anavo Therapeutics–SEVERAL: investment, 202305 seed financing round extenstion €8.5m with new investor MRL Ventures + all existing investors |
2023-05-02 |
| Medigene–Helmholtz: cancer immunotherapy, 202305– license ww excl to CD40L-CD28 costimulatory swith receptor from Helmholtz Munich |
2023-05-02 |
| Oculis–Consilium: public relations, 202303 service existent by CSC |
2023-05-02 |
| Ten23 Health–Bionter: particle counting, 202305– collab developm of methods incl installation of EVE particle counter at Ten23 Heatlh |
2023-05-02 |
| VectivBio–Forbion: investment, 202305 existent shareholder Forbion |
2023-05-01 |
| Clickmer Systems–APIS Assay Technologies: investment, 202204 acquisition of Clickmer Systems for single-digit €m by APIS Assay Technologies Ltd |
2023-04-25 |
| Forbion–SEVERAL: investment, 202304 final close of Forbion Growth Opportunities Fund II with addit €130m bringing total fund size to hard cap €600m |
2023-04-19 |
| Forbion–SEVERAL: investment, 202304 final close €750m of Forbion Ventures Fund VI |
2023-04-19 |
| Gilde Investment–SEVERAL: investment, 202304 announced new Gilde Healthcare Venture&Growth VI with €600m investor commitments |
2023-04-19 |
| Ariceum Therapeutics–Andera Partners: investment, 202304 financing round Series A extension totalling €22.75m incl new + co-lead investor Andera |
2023-04-18 |
| Ariceum Therapeutics–Bellevue: investment, 202304 financing round Series A extension totalling €22.75m incl existing + co-investor Pureos Bioventures |
2023-04-18 |
| Ariceum Therapeutics–Earlybird: investment, 202304 financing round Series A extension totalling €22.75m incl new + co-lead investor Earlybird VC |
2023-04-18 |
| Ariceum Therapeutics–SEVERAL: investment, 202304 financing round Series A extension €22.75m bringing total Series A to €47.75m |
2023-04-18 |
| Zetta Genomics–Apex Ventures: investment, 202304 2nd seed financing round totalling £1.9m incl existing + co-investor Apex Ventures |
2023-04-18 |
| Zetta Genomics–SEVERAL: investment, 202304 2nd seed financing round £1.9m with led by Nina Capital |
2023-04-18 |
| Zetta Genomics–Univ Cambridge: investment, 202304 2nd seed financing round totalling £1.9m incl existing + co-investor Cambridge Enterprise |
2023-04-18 |
| Bio-Techne–Lunaphore: spatial omics, 202304– collab strategic partnership integrating COMET system with RNAscope technology |
2023-04-17 |
| Complement Therapeutics–BioGeneration Ventures: investment, 202304 financing round Series A totalling €72m incl exising + co-investor BGV |
2023-04-17 |
| Complement Therapeutics–Cambridge Innovation Capital: investment, 202304 financing round Series A totalling €72m incl new + co-investor CIC |
2023-04-17 |
| Complement Therapeutics–Forbion: investment, 202304 financing round Series A totalling €72m incl exising + co-lead investor Forbion |
2023-04-17 |
| Complement Therapeutics–Gimv: investment, 202304 financing round Series A totalling €72m incl new + lead investor Gimv |
2023-04-17 |
| Complement Therapeutics–Hadean Ventures: investment, 202304 financing round Series A totalling €72m incl new + co-investor Hadean Ventures |
2023-04-17 |
| Complement Therapeutics–Panakès Partners: investment, 202304 financing round Series A totalling €72m incl new + co-investor Panakès Partners |
2023-04-17 |
| Complement Therapeutics–Seroba: investment, 202304 financing round Series A totalling €72m incl new + co-investor Seroba Life Sciences |
2023-04-17 |
| Complement Therapeutics–SEVERAL: investment, 202304 financing round Series A €72m led by new investor Gimv |
2023-04-17 |
| Syngenta–Ginkgo Bioworks: seed technology, 202304– collab research using protein engineering + uHTS technologies to design + develop new plant traits |
2023-04-17 |
| CellPhenomics–Kyan Therapeutics: drug development technology, 202304– collab combi Optim.AI technology with PD3D technology for drug development |
2023-04-14 |
| Alentis Therapeutics–Bellevue: investment, 202304 financing round Series C totalling $105m incl existing + co-investor BB Pureos Bioventures |
2023-04-13 |
| Alentis Therapeutics–France (govt): investment, 202304 financing round Series C totalling $105m incl existing + co-investor InnoBio 2 Fund |
2023-04-13 |
| Alentis Therapeutics–Jeito Capital: investment, 202304 financing round Series C totalling $105m incl existing + lead investor Jeito Capital |
2023-04-13 |
| Alentis Therapeutics–Novo Group: investment, 202304 financing round Series C totalling $105m incl new + co-lead investor Novo Holdings A/S |
2023-04-13 |
| Alentis Therapeutics–RA Capital: investment, 202304 financing round Series C totalling $105m incl new + co-lead investor RA Capital Management |
2023-04-13 |
| Alentis Therapeutics–Schroders: investment, 202304 financing round Series C totalling $105m incl existing + co-investor Schroders Capital |
2023-04-13 |
| Alentis Therapeutics–SEVERAL: investment, 202304 financing round Series C $105m led by Jeito Capital with Novo Holdings + RA Capital |
2023-04-13 |
| InflaRx–SEVERAL: investment, 202304 public offering $40m + $6m with 9.4m + 1.4m ordinary shares at $4.25/share |
2023-04-11 |
| Merck (US)–Proxygen: molecular glue degraders, 202304– strategic multi-year collab + license agreem upfront payment + €2.55b milestones plus royalties |
2023-04-05 |
| Proxygen–Vida Strategic Partners: public relations, 202304 service existent by Vida Strategic Partners |
2023-04-05 |
| AMSilk–Cargill: investment, 202304 financing round Series C extension totalling €24m incl existing + co-investor Cargill |
2023-04-04 |
| AMSilk–MIG Fonds: investment, 202304 financing round Series C extension totalling €24m incl existing + co-investor MIG Capital |
2023-04-04 |
| AMSilk–Novo Group: investment, 202304 financing round Series C extension totalling €24m incl existing + co-investor Novo Holdings |
2023-04-04 |
| AMSilk–Optimum Strategic Communications: public relations, 202304 service existent by Optimum |
2023-04-04 |
| AMSilk–SEVERAL: investment, 202304 financing round Series C extension €24m led by AT Newtec bringing total round to €54m |
2023-04-04 |
| AMSilk–Strüngmann Group: investment, 202304 financing round Series C extension totalling €24m incl existing + lead investor Athos (AT Newtec) |
2023-04-04 |
| Biocartis–APIS Assay Technologies: molecular diagnostics, 202304– collab developm + commerc APIS Breast Cancer Subtyping assay on Idylla platform |
2023-04-04 |
| Point Biopharma–Eckert & Ziegler: radiopharmaceuticals, 202304– supply of nca actinum-225 to Point Biopharma |
2023-04-04 |
| Precirix–Optimum Strategic Communications: public relations, 202203 service existent by Optimum |
2023-04-04 |
| BioNTech–Duality Biologics: antibody-drug conjugates, 202304– license excl ww excl China for DB-1303 + DB-1311 $170m upfront + >$1.5b milestones + roy |
2023-04-03 |
| InSphero–Carl Zeiss: investment, 202303 financing round totalling 8-digit incl lead investor Zeiss Ventures |
2023-03-31 |
| InSphero–SEVERAL: investment, 202303 financing round 8-digit led by Zeiss Ventures |
2023-03-31 |
| Polyplus-transfection–Sartorius: investment, 202303– acquisition €2.4b of Polyplus by SSB from Archimed + Warburg Pincus et al |
2023-03-31 |
| BMS–Evotec: drug discovery services, 202303–203102 strategic RnD collab expansion 8 years $50m upfront + total potential $4b neurodegenerative drugs |
2023-03-28 |
| Deepc–Bertelsmann: investment, 202303 financing round Series A totalling €12m incl new + co-investor Bertelsmann Investments |
2023-03-28 |
| Deepc–SEVERAL: investment, 202303 financing round Series A €12m led by Sofinnova Partners |
2023-03-28 |
| Deepc–Sofinnova: investment, 202303 financing round Series A totalling €12m incl new + lead investor Sofinnova Partners |
2023-03-28 |
| Deepc–Winning Mindset Ventures: investment, 202303 financing round Series A totalling €12m incl existing + co-investor Winning Mindset Ventures |
2023-03-28 |
| Novartis–Bicycle Therapeutics: Bicycle technology, 202303– strategic collab $50m upfront + $1.7b milestones for targeted radiopharmaceuticals |
2023-03-28 |
| Thermosome–Akampion: public relations, 202303 service existent by Akampion |
2023-03-28 |
| SolasCure–BRAIN Biotech: investment, 202303 financing round Series B totalling £10.9m incl existing + co-investor BRAIN Biotech |
2023-03-27 |
| SolasCure–EVA Pharma: investment, 202303 financing round Series B totalling £10.9m incl co-investor EVA Pharma |
2023-03-27 |
| SolasCure–PERSON: investment, 202303 financing round Series B totalling £10.9m incl investor Jonathan Milner |
2023-03-27 |
| SolasCure–Seneca Partners: investment, 202303 financing round Series B totalling £10.9m incl existing + lead investor Seneca Partners |
2023-03-27 |
| SolasCure–SEVERAL: investment, 202303 financing round Series B £10.9m led by Seneca Partners |
2023-03-27 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 ... 9 10 11 ... 39 40 41 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
